Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

ESMO Guidelines Committee

doi:10.1016/j.annonc.2022.12.013

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up^☆

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

152 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	358-376
Nombre de pages	19
journal	Annals of Oncology
Volume	34
Numéro de publication	4
Les DOIs	https://doi.org/10.1016/j.annonc.2022.12.013
état	Publié - 1 avr. 2023

Accès au document

10.1016/j.annonc.2022.12.013

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{abdea7412b2d47eca8ce0f002e2a5c82,

title = "Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆",

keywords = "ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, immunotherapy, non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy",

author = "{ESMO Guidelines Committee} and Hendriks, {L. E.} and Kerr, {K. M.} and J. Menis and Mok, {T. S.} and U. Nestle and A. Passaro and S. Peters and D. Planchard and Smit, {E. F.} and Solomon, {B. J.} and G. Veronesi and M. Reck",

note = "Funding Information: Manuscript editing support was provided by Fraser Simpson, Claire Bramley and Catherine Evans ( ESMO Guidelines staff); this support was funded by ESMO . Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urania Dafni, ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino ( ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores, and Angela Corstorphine of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO . Matt Hellmann provided initial writing support during the conception of this guideline. ",

year = "2023",

month = apr,

day = "1",

doi = "10.1016/j.annonc.2022.12.013",

language = "English",

volume = "34",

pages = "358--376",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "4",

}

TY - JOUR

T1 - Non-oncogene-addicted metastatic non-small-cell lung cancer

T2 - ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

AU - ESMO Guidelines Committee

AU - Hendriks, L. E.

AU - Kerr, K. M.

AU - Menis, J.

AU - Mok, T. S.

AU - Nestle, U.

AU - Passaro, A.

AU - Peters, S.

AU - Planchard, D.

AU - Smit, E. F.

AU - Solomon, B. J.

AU - Veronesi, G.

AU - Reck, M.

N1 - Funding Information: Manuscript editing support was provided by Fraser Simpson, Claire Bramley and Catherine Evans ( ESMO Guidelines staff); this support was funded by ESMO . Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urania Dafni, ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino ( ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores, and Angela Corstorphine of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO . Matt Hellmann provided initial writing support during the conception of this guideline.

PY - 2023/4/1

Y1 - 2023/4/1

KW - ESCAT

KW - ESMO Clinical Practice Guideline (CPG)

KW - ESMO-MCBS

KW - immunotherapy

KW - non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC)

KW - treatment, targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85152568235&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2022.12.013

DO - 10.1016/j.annonc.2022.12.013

M3 - Article

C2 - 36669645

AN - SCOPUS:85152568235

SN - 0923-7534

VL - 34

SP - 358

EP - 376

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -